article thumbnail

Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body

GeekWire

Less than three years after it was founded and with no revenue on the books, Sana Biotechnology has f iled to go public. While Sana says its approach is applicable to a number of diseases, some of its most advance research is being done around cancer. And like many biotechnology companies it is losing money. stake in Sana.

article thumbnail

Sana Biotechnology will cut 15% of its workforce in latest layoffs affecting Seattle companies

GeekWire

Seattle-based cell and gene therapy company Sana Biotechnology will reduce its workforce by 15%, according to a statement issued Tuesday. Adaptive Biotechnologies , Absci , and Zymeworks also announced layoffs this year. Sana expects to file its first investigational new drug application (IND) this year with the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sana Biotechnology boosts IPO range, looks to raise $517 million

GeekWire

Sana Biotechnology — the Seattle upstart that’s looking to treat a variety of diseases through gene therapy and cell engineering — is generating buzz on Wall Street. That would net the biotechnology company $517 million if it sold at the midpoint of that range. Sana’s technology (screen grab via IPO filing).

article thumbnail

Sana Biotechnology inks $50M deal for precise gene editing system from Beam Therapeutics

GeekWire

Sana Biotechnology has a new $50 million tool in its toolbox. SANA intends to file its first investigational new drug application incorporating the new gene editing platform as early as next year, said Harr. The application with the U.S. Sana CEO and president Steve Harr. Sana Photo).

article thumbnail

Adaptive Biotechnologies’ new HQ: Co-founders show off 100K square-foot space in Seattle

GeekWire

Adaptive co-founders Harlan (left) and Chad Robins on the plaza at the new Adaptive Biotechnology headquarters. After doubling its workforce during the pandemic, Adaptive Biotechnologies finally has room to grow. Next year the companies expect to file an investigational new drug application with the U.S.

article thumbnail

Machine learning and microbes: How big data is redefining biotechnology

Tech Republic Big Data

As interesting as big data can be in Silicon Valley, its most fascinating applications often happen elsewhere.

Big Data 111
article thumbnail

GeekWire Awards: How these five Workplace of the Year finalists navigate challenging times

GeekWire

Workplace of the Year finalists, clockwise from top left: Adaptive Biotechnologies co-founders Harlan and Chad Robins; the Helion team; Impinj offices in Seattle; Treasury4 team; Blink CEO Karen Clark Cole. This year’s finalists are Adaptive Biotechnologies, Blink, Helion, Impinj and Treasury4. Blink Blink CEO Karen Clark Cole.